Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck
Trial details
- Registry ID
- NCT03083873
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as TIL, Autologous Tumor Infiltrating Lymphocytes; TIL, autologous tumor infiltrating lymphocytes
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & NeckNCT03083873 | IOVA | Phase 2 | Completed | 2022-08-08Actual |
| Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical CarcinomaNCT03108495 | IOVA | Phase 2 | Terminated | 2025-08-22Actual |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung CancerNCT04614103 | IOVA | Phase 2 | Recruiting | 2030-12Estimated |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid TumorsNCT03645928 | IOVA | Phase 2 | Terminated | 2026-02-20Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |